Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Finished

ONCOMAC Allogeneic Macrophages for Cancer Therapy

Coordinator
Technische Universitaet Dresden, Germany
Runs
1 May 2022 to 31 October 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069255

What the project is doing

In the project's own words, from its summary on CORDIS.

Macrophage cell therapy can become an attractive example of a cell therapy, with numerous potential applications, among them cancer therapy. While T-cell based therapies so successful for the treatment of hematological malignancies! have yet failed to demonstrate effectiveness in the treatment of solid tumors, macrophages are a key component of the tumor microenvironment (TME), and in principle they are capable of killing solid tumor cells.

However, wildtype macrophages commonly respond to the TME by acquisition of a M2-like polarization state, in which state they rather support tumor growth and metastatic spread. This is a first problem for macrophage cell therapy against cancer. Besides, unlike T-cells, human macrophages cannot be expanded in cell culture, resulting in insufficient numbers of obtainable macrophages and thus limiting their utility for cell therapy.

We have generated genetically engineered human macrophages, which have proliferative potential, are resistent to tumor-induced repolarization and thus demonstrate oncolytic activity. We want to translate these exciting findings into a cell-therapy against cancer. ONCOMAC relates to the preparation for and design of a preclinical proof-of-concept study for these genetically engineered human macrophages, so that we will have a sound basis for the translation of our genetically engineered macrophages into clinical trials.

In particular, ONCOMAC will establish the numerous complex analytical procedures which are required by the European Medicine Agency's regulatory framework for First-in-human studies of an ATMP (Advanced Therapy Medicinal Product).

Topics

Who is involved

OrganisationCityCountryRole
Technische Universitaet DresdenDresdenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI